drugset / Trial / NCT01040559
Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximal tolerated dose of idarubicin for chemoembolization of non resectable non metastatic hepatocellular carcinoma.
Timeline
- Start
- 2009-12
- Primary completion
- 2011-12
- Completion
- 2012-06
Publications
- Anota A, Boulin M, Dabakuyo-Yonli S, Hillon P, Cercueil JP, Minello A, Jouve JL, Paoletti X, Bedenne L, Guiu B, Bonnetain F. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma. BMJ Open. 2016 Jun 24;6(6):e010696. doi: 10.1136/bmjopen-2015-010696.
- Boulin M, Hillon P, Cercueil JP, Bonnetain F, Dabakuyo S, Minello A, Jouve JL, Lepage C, Bardou M, Wendremaire M, Guerard P, Denys A, Grandvuillemin A, Chauffert B, Bedenne L, Guiu B. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther. 2014 Jun;39(11):1301-13. doi: 10.1111/apt.12746. Epub 2014 Apr 16.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idarubicin | Small molecule | 5 mg | Other |
| Subject | Idarubicin | Small molecule | 10 mg | Other |
| Subject | Idarubicin | Small molecule | 15 mg | Other |
| Subject | Idarubicin | Small molecule | 20 mg | Other |
| Subject | Idarubicin | Small molecule | 25 mg | Other |